Home » News » December 2020

December, 2020

Significant Refundable R&D Offsets Receipts Reported to ASX, ATO Reviews Still Occurring

December 14th, 2020

Over recent months, a number of companies have reported to the ASX receipt of substantial Refundable R&D Offsets. Notable receipts include: Zelira Therapeutics’ receipt of $1.4 M in December for cannabis medicines; Imugene’s receipt of $4.82M in December for Immuno-oncology research activities; Agrimin’s receipt of $1.6M in December for development of a potash project; Anteotech’s receipt of $1.2M in November for Surface chemistry activities; Bluechiip’s receipt of $1.5M in November for wireless tracking solutions; Intelicare Holdings’ receipt of $0.41M in […]

Read More

Australia’s R&D Tax Incentive and Clinical Sector To Be Showcased During JP Morgan Week

December 7th, 2020

AusBiotech’s virtual showcase during JP Morgan week in January 2021 will seek to highlight the advantages of partnering with Australian life science companies and utilising the R&D Tax Incentive. Australia has become an attractive location for the conduct of clinical trials in recent years, based on local capability and infrastructure offering companies the ability to attain high-quality clinical data. Australia’s 43.5% Refundable R&D Tax Offset has further made the country an attractive destination for the conduct of clinical research. Ausbiotech’s […]

Read More

Categories

Archives